Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections (VOD)

Fraser Health

Status

Completed

Conditions

Skin and Soft Tissue Infections

Treatments

Drug: vancomycin

Study type

Interventional

Funder types

Other

Identifiers

NCT01037192

VOD

Details and patient eligibility

About

Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for skin and soft tissue infections in an outpatient setting.

Enrollment

4 patients

Sex

All

Ages

19 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age 19 to 70 years
Weight 40 - 80 kg
Suspected or confirmed skin or soft tissue infection for which vancomycin is indicated
Subject referred to or admitted into OPAT by an Infectious Disease Specialist or Emergency Physician
Subject able to provide informed consent

Exclusion criteria

Known history of allergy to vancomycin
Pregnancy
Granulocytopenia (< 1x109/L)
Renal impairment (serum creatinine > 177 µmol/L or eGFR < 50 mL/min)
Known history of vestibular disease or hearing loss
Subjects treated with vancomycin within the previous month
Subjects who have received more than 24 hours of vancomycin
Subjects receiving other antimicrobials that cover MRSA (e.g. cotrimoxazole, rifampin, linezolid)